Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Catalent and Supernus Partner for Supply of Trokendi XR™

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
A novel, oral, once-daily formulation of topiramate for the treatment of epilepsy.

Catalent Pharma Solutions and Supernus Pharmaceuticals have entered into an agreement where Catalent is the supplier of Trokendi XR™ extended release capsules for Supernus.

Supernus developed Trokendi XR using its own advanced drug delivery technology and transferred its formulation to Catalent for commercial manufacturing.

“Supernus selected Catalent as our commercial supply partner based on their extensive experience in manufacturing extended release products, the longstanding relationship we have had with them, and a proven track record of high quality.” said Jack Khattar, Chief Executive Officer, President and Director of Supernus.

Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business, said “We offer customers integrated solutions that include both proprietary drug delivery technologies and advanced supply solutions for oral controlled release development and commercial products. We are pleased to have been selected by Supernus to work on this unique epilepsy product.”

Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the US market.

Trokendi XR delivers an extended-release form of topiramate, one of the most effective anti epilepsy drugs.

Trokendi XR is a convenient once per day alternative to current immediate release formulation products which require patients to administer their medication multiple times per day.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Catalent Biologics, Moderna Therapeutics Collaborate
Collaboration aims to support near-term clinical GMP mRNA manufacturing efforts for Phase 1/2 clinical studies of the company’s mRNA personalized cancer vaccines.
Saturday, October 22, 2016
Catalent, Zumutor Collaborate
Collaboration aims to develop antibodies with enhanced ADCC activity.
Friday, August 05, 2016
Catalent, Palatin Technologies Announce Agreement
Partnership aims to support the product launch of Palatin’s bremelanotide pen injector product, which is used to treat FSD.
Thursday, July 07, 2016
Catalent Launches FastChain Service
Company has announced the launch of its FastChain service to meet increasing need for speed & flexibility in global clinical trials.
Thursday, June 30, 2016
Catalent Announces Appointment of Sally Langa
Appointment of Ms. Langa as new Vice President of Development and Analytical Services.
Friday, January 29, 2016
Catalent to Open New Clinical Supply Facility in Japan
Construction is expected to be validated and operational in the second quarter of 2016.
Thursday, January 21, 2016
Catalent Announces Research Collaboration with Roche
Collaboration focuses on development of novel molecules using SMARTag technology to couple different therapeutic modalities.
Thursday, January 14, 2016
Catalent Biologics Announces the Appointment of Kevin Hambly
Company appoints Mr. Hambly to the position of Vice President, Business Development and Licensing.
Tuesday, December 15, 2015
Catalent Biologics Expands Capabilities
Company announces multi-site expansion of its analytical and process development capabilities.
Thursday, November 26, 2015
Catalent Biologics Adds New Technology Platform
Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.
Thursday, July 09, 2015
Catalent Awarded Grant as Part of Vaccine Research Consortium
Goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
Friday, April 24, 2015
Catalent & Sanofi to Collaborate
Collaboration on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies.
Thursday, January 22, 2015
Catalent and SELLAS Sign Exclusive Agreement
Agreement for therapeutic reprofiling of zolpidem.
Friday, December 12, 2014
Catalent and Valerion Therapeutics Collaborate
Collaboration to bring new treatments for orphan genetic disorders to market.
Thursday, December 04, 2014
Catalent Acquires Micron Technologies
Company adds global particle size technology leader to Industry’s broadest bioavailability and delivery technology offerings.
Friday, November 21, 2014
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Anti-Inflammatory Drugs Could Help Treat Depression
Anti-inflammatory drugs could be used to treat some cases of depression, which further implicates our immune system in mental health disorders.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Painting the Way to Tumour Imaging
Tumour paint used in emergency surgery to aid cell identification for surgeons.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Targeting Estrogen Receptor Improves Survival in Breast Cancer
Trial finds estrogen receptor degrader significantly increases progression-free survival in patients with advanced breast cancer.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
Alzheimer’s Linked Protein Can Be Removed From Brain Without Hindering Memory, Learning
Researchers at UTSW have found that the mice can maintain their learning and memory when virtually all ApoE is removed from the brain but kept present in the liver to filter cholesterol.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos